When Aveo Pharmaceuticals found itself floundering three years ago in the wake of the FDA’s rejection of its lead cancer drug, Novartis threw out a lifeline: a partnership on another Aveo drug that would finance its development. Now Novartis is pulling that support away. Novartis (NYSE: NVS) is ending the partnership on the compound AV-380, […]
Original Article: Priority Changes for Novartis Spell the End for Aveo Pharma Alliance